MedPath

Cedeño Jara Alan Joel

🇪🇨Ecuador
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

1

Active:0
Completed:0

Trial Phases

1 Phases

Phase 3:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials

Phase 3
1 (100.0%)

ONCONASE Plus Doxorubicin Versus Doxorubicin Alone For Patients With Malignant Pleural or Peritoneal Mesothelioma Who Have Had No More Than One Prior Chemotherapy Regimen

Phase 3
Conditions
Malignant Mesothelioma
Interventions
First Posted Date
2003-01-27
Last Posted Date
2013-11-06
Lead Sponsor
Alfacell
Target Recruit Count
300
Registration Number
NCT00003034
Locations
🇺🇸

CCOP - Northern Indiana CR Consortium, South Bend, Indiana, United States

🇺🇸

Greenebaum Cancer Center at University of Maryland Medical Center, Baltimore, Maryland, United States

🇺🇸

Spectrum Health Hospital - Butterworth Campus, Grand Rapids, Michigan, United States

and more 16 locations

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.